MCID: HML001
MIFTS: 50

Hemolytic-Uremic Syndrome

Categories: Rare diseases, Immune diseases, Blood diseases, Nephrological diseases

Aliases & Classifications for Hemolytic-Uremic Syndrome

MalaCards integrated aliases for Hemolytic-Uremic Syndrome:

Name: Hemolytic-Uremic Syndrome 12 76 29 55 44 15 73
Hemolytic Uremic Syndrome 12 53
Acute Renal Failure, Thrombocytopenia, and Microangiopathic Hemolytic Anemia Associated with Distorted Erythrocytes 53
Haemolytic-Uraemic Syndrome 12
Hus 53

Classifications:



External Ids:

Disease Ontology 12 DOID:12554
ICD10 33 D59.3
ICD9CM 35 283.11
MeSH 44 D006463
NCIt 50 C75545
SNOMED-CT 68 111407006 123308008
UMLS 73 C0019061

Summaries for Hemolytic-Uremic Syndrome

NIH Rare Diseases : 53 Hemolytic uremic syndrome (HUS) is a disorder that usually occurs when an  E. coli bacterial infection in the digestive system produces toxic substances that destroy red blood cells. Symptoms include vomiting and diarrhea, fever, lethargy, and weakness. In severe cases it can lead to kidney failure or death. While this condition is most common in children, it often has a more complicated presentation in adults. Treatment may include dialysis, corticosteroids, transfusions of packed red blood cells and plasmapheresis.   Hemolytic uremic syndrome should be distinguished from atypical hemolytic uremic syndrome (aHUS). The two conditions have different causes and different signs and symptoms.

MalaCards based summary : Hemolytic-Uremic Syndrome, also known as hemolytic uremic syndrome, is related to nephrotic syndrome, type 7 and complement factor h deficiency. An important gene associated with Hemolytic-Uremic Syndrome is CFH (Complement Factor H), and among its related pathways/superpathways are Creation of C4 and C2 activators and Complement Pathway. The drugs Complement System Proteins and Shiga Toxins have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and liver, and related phenotype is renal/urinary system.

Disease Ontology : 12 A kidney disease that is characterized by hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney and other organs.

Wikipedia : 76 Hemolytic-uremic syndrome (HUS) is a disease characterized by a triad of hemolytic anemia (anemia caused... more...

Related Diseases for Hemolytic-Uremic Syndrome

Diseases in the Hemolytic-Uremic Syndrome family:

D-Plus Hemolytic Uremic Syndrome

Diseases related to Hemolytic-Uremic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 170)
# Related Disease Score Top Affiliating Genes
1 nephrotic syndrome, type 7 34.1 CFH DGKE
2 complement factor h deficiency 32.7 CD46 CFH CFHR1 CFI
3 hemolytic uremic syndrome, atypical 1 32.5 CFH CFHR1 CFHR3 CFHR4 CFHR5 DGKE
4 purpura 30.9 ADAMTS13 THBD VWF
5 glomerulonephritis 30.8 C3 CFH CFHR5 CFI
6 proliferative glomerulonephritis 30.4 C3 CFH
7 catastrophic antiphospholipid syndrome 30.4 ADAMTS13 CFH
8 thrombotic thrombocytopenic purpura 30.1 ADAMTS13 CD46 CFH THBD VWF
9 thrombotic thrombocytopenic purpura, acquired 30.1 ADAMTS13 VWF
10 membranoproliferative glomerulonephritis 30.0 C3 CD46 CFB CFH CFHR5
11 c3 glomerulopathy 29.7 C3 CFB CFHR1 CFHR3 CFHR5
12 hemolytic anemia 29.6 ADAMTS13 CFH CFI VWF
13 hellp syndrome 28.7 ADAMTS13 CD46 CFH CFI THBD VWF
14 enterocolitis 28.5 C3 CD46 CFB CFH CFHR5 CFI
15 macular degeneration, age-related, 1 26.6 C3 CD46 CFB CFH CFHR1 CFHR3
16 hemolytic uremic syndrome, atypical 3 12.6
17 hemolytic uremic syndrome, atypical 4 12.6
18 hemolytic uremic syndrome, atypical 5 12.6
19 hemolytic uremic syndrome, atypical 6 12.6
20 hemolytic uremic syndrome, atypical 2 12.6
21 hemolytic uremic syndrome, atypical, childhood 12.5
22 genetic atypical hemolytic-uremic syndrome 12.4
23 d-minus hemolytic uremic syndrome 12.2
24 d-plus hemolytic uremic syndrome 12.2
25 atypical hemolytic-uremic syndrome with h factor anomaly 12.2
26 shigellosis 11.6
27 combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia 11.3
28 pancreatitis, pediatric 11.2
29 de novo thrombotic microangiopathy after kidney transplantation 10.8 CFH CFI
30 familial drusen 10.8 CFH CFI
31 multifocal choroiditis 10.7 CFB CFH
32 complement factor i deficiency 10.7 C3 CFI
33 choroiditis 10.6 CFB CFH
34 diarrhea 10.6
35 pneumonia 10.5
36 retinal drusen 10.5 C3 CFB CFH
37 complement component 3 deficiency 10.5 C3 CFB CFI
38 thrombotic thrombocytopenic purpura, congenital 10.5 ADAMTS13 CFH
39 neisseria meningitidis infection 10.5 C3 CD46
40 endotheliitis 10.5
41 methylmalonic aciduria and homocystinuria, cblc type 10.5 CD46 DGKE
42 unilateral absence of a pulmonary artery 10.4 THBD VWF
43 pancreatitis 10.4
44 lyme disease 10.4 C3 CFH CFHR1
45 encephalopathy 10.3
46 aging 10.3
47 colitis 10.3
48 malignant hypertension 10.3
49 anuria 10.3
50 influenza 10.3

Comorbidity relations with Hemolytic-Uremic Syndrome via Phenotypic Disease Network (PDN):


Acute Kidney Failure Chronic Kidney Failure
Deficiency Anemia Heart Disease

Graphical network of the top 20 diseases related to Hemolytic-Uremic Syndrome:



Diseases related to Hemolytic-Uremic Syndrome

Symptoms & Phenotypes for Hemolytic-Uremic Syndrome

MGI Mouse Phenotypes related to Hemolytic-Uremic Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.1 CFI THBD C3 C5 CFB CFH

Drugs & Therapeutics for Hemolytic-Uremic Syndrome

Drugs for Hemolytic-Uremic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Complement System Proteins Phase 2, Phase 3,Phase 3
2 Shiga Toxins Phase 2, Phase 3,Phase 3,Phase 1
3 Antibodies Phase 3,Phase 2
4 Immunoglobulins Phase 3,Phase 2
5 Pharmaceutical Solutions Phase 3,Phase 1,Not Applicable
6 Complement Inactivating Agents Phase 3
7 Antibodies, Bispecific Phase 3
8 Coagulants Phase 3
9 Factor VIII Phase 3
10
Acetaminophen Approved Phase 2 103-90-2 1983
11
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
12
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
13
Promethazine Approved, Investigational Phase 2 60-87-7 4927
14
rituximab Approved Phase 2 174722-31-7 10201696
15
Bevacizumab Approved, Investigational Phase 2 216974-75-3
16
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
17
Everolimus Approved Phase 2 159351-69-6 6442177
18
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
19
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
20
Vinblastine Approved Phase 2 865-21-4 13342 241903
21
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
22
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
23 Antirheumatic Agents Phase 2
24 Antibodies, Monoclonal Phase 2
25 Alkylating Agents Phase 2
26 Angiogenesis Inhibitors Phase 2
27 Angiogenesis Modulating Agents Phase 2
28 Anti-Bacterial Agents Phase 2
29 Antibiotics, Antitubercular Phase 2
30 Antifungal Agents Phase 2
31 Anti-Infective Agents Phase 2
32 Antimitotic Agents Phase 2
33 Antineoplastic Agents, Alkylating Phase 2
34 Antineoplastic Agents, Phytogenic Phase 2
35 Endothelial Growth Factors Phase 2
36 Immunoglobulin G Phase 2
37 Immunosuppressive Agents Phase 2
38 Mitogens Phase 2
39 Immunotoxins Phase 1, Phase 2,Phase 2
40 BB 1101 Phase 2
41 Dexamethasone acetate Phase 2 1177-87-3
42
Metoclopramide Approved, Investigational Not Applicable 364-62-5 4168
43 dipyrone Not Applicable
44 Natriuretic Agents Not Applicable
45 Natriuretic Peptide, Brain Not Applicable
46 Antibodies, Blocking

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Active, not recruiting NCT02574403 Phase 4 eculizumab
2 Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment Active, not recruiting NCT02614898 Phase 4
3 Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) Completed NCT01410916 Phase 2, Phase 3 Eculizumab (Soliris®)
4 Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome Recruiting NCT03205995 Phase 3
5 Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting NCT03131219 Phase 3
6 Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting NCT02949128 Phase 3
7 Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU Recruiting NCT02205541 Phase 3 Eculizumab;Placebo
8 A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Recruiting NCT03191799 Phase 3 Emicizumab
9 Improvements Through the Use of a Rapid Multiplex PCR Enteric Pathogen Detection Kit in Children With Hematochezia Recruiting NCT03362970 Phase 3
10 Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome Terminated NCT00004465 Phase 3 SYNSORB Pk;Placebo
11 The Plasma Large-Volume Exchange RCT Withdrawn NCT01433003 Phase 3
12 Rituximab in Patients With Relapsed or Refractory TTP-HUS Unknown status NCT00531089 Phase 2 Rituximab
13 Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies Unknown status NCT02222545 Phase 2
14 An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome Completed NCT01194973 Phase 2 Eculizumab
15 An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome Completed NCT01193348 Phase 2 Eculizumab
16 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT00838513 Phase 2 eculizumab
17 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS Completed NCT00844545 Phase 2 Eculizumab
18 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS Completed NCT00844844 Phase 2 Eculizumab
19 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS Completed NCT00844428 Phase 2 eculizumab
20 The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT01757431 Phase 2 Eculizumab
21 Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2 Completed NCT01252199 Phase 2 cαStx1/cαStx2;Placebo
22 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Completed NCT01222715 Phase 2 Cyclophosphamide;Temsirolimus;Vinorelbine Tartrate
23 Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) Completed NCT01030536 Phase 1, Phase 2 CAT-8015 20 mcg/kg;CAT-8015 30 mcg/kg;CAT-8015 40 mcg/kg;CAT-8015 50 mcg/kg;CAT-8015 60 mcg/kg
24 A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome Recruiting NCT03303313 Phase 2 Cemdisiran
25 Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Not yet recruiting NCT03518203 Phase 2 Eculizumab
26 Complement Inhibition in aHUS Dialysis Patients Terminated NCT02464891 Phase 2 CCX168
27 Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT02338050 Phase 2
28 Shiga Toxin Producing Escherichia Coli (STEC) Volume Expansion Not yet recruiting NCT03275792 Phase 1 D5-0.9%NS;Routine home oral rehydration
29 Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease Unknown status NCT00930423
30 Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 Completed NCT01406288
31 A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT01770951
32 Haemolytic Uraemic Syndrome in Childhood: Clinical, Cognitive and Psychological Aspects Completed NCT01666548
33 To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients Completed NCT01755429
34 Study of Repetitive Intestinal Lavage in Patients With EHEC Associated Hemorrhagic Colitis Completed NCT01561248 Not Applicable polyethylene glycol solution for daily bowel lavage.
35 The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury) Completed NCT00358306
36 Promising Bimarker Prediction of Outcome of HELLP Syndrome. Completed NCT03246542
37 Early Predictive Factors of Cardiac and Cerebral Involvement in TMA Completed NCT02134171 Not Applicable
38 Atypical Hemolytic-Uremic Syndrome (aHUS) Registry Recruiting NCT01522183
39 Study of 'Vascular Competence' Profile and Endothelial Activation in the Hemolytic Uremic Syndrome in Children and Adults Recruiting NCT02904863 Not Applicable
40 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Recruiting NCT01793168
41 Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment Recruiting NCT01087333
42 Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series Active, not recruiting NCT03574506
43 Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy Active, not recruiting NCT03580941
44 The Role of Microparticles as a Biomarker Enrolling by invitation NCT02626663
45 aHUS Observational Long Term Follow-Up Terminated NCT01522170
46 International Registry and Biorepository for TMA(Thrombotic Microangiopathy) Terminated NCT00593229

Search NIH Clinical Center for Hemolytic-Uremic Syndrome

Cochrane evidence based reviews: hemolytic-uremic syndrome

Genetic Tests for Hemolytic-Uremic Syndrome

Genetic tests related to Hemolytic-Uremic Syndrome:

# Genetic test Affiliating Genes
1 Hemolytic-Uremic Syndrome 29

Anatomical Context for Hemolytic-Uremic Syndrome

MalaCards organs/tissues related to Hemolytic-Uremic Syndrome:

41
Kidney, Endothelial, Liver, Brain, B Cells, Monocytes, Lung

Publications for Hemolytic-Uremic Syndrome

Articles related to Hemolytic-Uremic Syndrome:

(show top 50) (show all 936)
# Title Authors Year
1
Kidney Transplantation in Patients with Atypical Hemolytic Uremic Syndrome due to Complement Factor H Deficiency: Impact of Liver Transplantation. ( 29215813 )
2018
2
Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia. ( 29858280 )
2018
3
Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype andA outcome. ( 29907460 )
2018
4
Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). ( 29372302 )
2018
5
Atypical Presentation of Pregnancy-Related Hemolytic Uremic Syndrome. ( 29331477 )
2018
6
Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy? ( 29808447 )
2018
7
An outbreak of hemolytic uremic syndrome in southern Romania during 2015-2016: Epidemiologic, clinical, laboratory, microbiologic, therapeutic and outcome characteristics. ( 29807724 )
2018
8
CCR2-dependent Gr1high monocytes promote kidney injury in shiga toxin-induced hemolytic uremic syndrome in mice. ( 29446073 )
2018
9
Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology. ( 29796581 )
2018
10
Case Series of 3 Patients Diagnosed With Atypical Hemolytic Uremic Syndrome Successfully Treated With Steroids, Plasmapheresis, and Rituximab. ( 29308213 )
2018
11
Atypical hemolytic uremic syndrome: An unusual postoperative complication. ( 29426622 )
2018
12
Gastrointestinal pathogens in anti-FH antibody positive and negative Hemolytic Uremic Syndrome. ( 29795200 )
2018
13
Thrombomodulin and Endothelial Dysfunction: A Disease-Modifier Shared between Malignant Hypertension and Atypical Hemolytic Uremic Syndrome. ( 29940557 )
2018
14
Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab. ( 29768958 )
2018
15
Poststreptococcal glomerulonephritis with atypical hemolytic uremic syndrome: An unusual presentation. ( 29970754 )
2018
16
C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction. ( 29594148 )
2018
17
Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. ( 29500241 )
2018
18
Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. ( 29959568 )
2018
19
Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. ( 29356300 )
2018
20
50 Years Ago in The Journal of Pediatrics: The Hemolytic-Uremic Syndrome: Renal Status of 76 Patients at Long-Term Follow-Up. ( 29801537 )
2018
21
Atypical adult-onset methylmalonic acidemia and homocystinuria presenting as hemolytic uremic syndrome. ( 29294253 )
2018
22
Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. ( 29288280 )
2018
23
Atypical Hemolytic Uremic Syndrome. ( 29803280 )
2018
24
Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome. ( 29961127 )
2018
25
A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome. ( 29434134 )
2018
26
Glucose-6-Phosphate Dehydrogenase Deficiency Mimicking Atypical Hemolytic Uremic Syndrome. ( 29248304 )
2018
27
Ulcerative Colitis and Atypical Hemolytic-Uremic Syndrome: An Unusual But Potentially Life-threating Life Complication. ( 29931191 )
2018
28
Hemolytic uremic syndrome caused by Aeromona caviae in a pediatric patient. ( 29779570 )
2018
29
Streptococcus pneumoniae-associated Hemolytic Uremic Syndrome. ( 29417459 )
2018
30
Gastrointestinal Bleeding after Hemolytic Uremic Syndrome: A Report of Drug-Associated Granulation Tissue Polyps. ( 29851764 )
2018
31
Experimental <i>in vivo</i> models of bacterial Shiga toxin-associated hemolytic uremic syndrome. ( 29926707 )
2018
32
Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes. ( 29979220 )
2018
33
Importance of case age in the purported association between phylogenetics and hemolytic uremic syndrome in Escherichia coli O157:H7 infections. ( 29914582 )
2018
34
L-FABP and IL-6 as markers of chronic kidney damage in children after hemolytic uremic syndrome. ( 29905409 )
2018
35
A devastating case of diarrhea-associated hemolytic uremic syndrome associated with extensive cerebral infarction; why we need to do better. ( 28599619 )
2017
36
Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome and Catastrophic Antiphospholipid Syndrome. ( 29308852 )
2017
37
Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. ( 28056875 )
2017
38
Hemolytic-uremic Syndrome Complicating Acute Pancreatitis. ( 28904486 )
2017
39
Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation. ( 28057640 )
2017
40
Familial hemolytic uremic syndrome with occurrence in the postpartum period. ( 29265059 )
2017
41
Late Onset Cobalamin Disorder and Hemolytic Uremic Syndrome: A Rare Cause of Nephrotic Syndrome. ( 28835862 )
2017
42
Efficacy of eculizumab in an adult patient with HIV-associated hemolytic uremic syndrome: A case report. ( 29390523 )
2017
43
Blood urea nitrogen to serum creatinine ratio is an accurate predictor of outcome in diarrhea-associated hemolytic uremic syndrome, a preliminary study. ( 28078430 )
2017
44
Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. ( 28750931 )
2017
45
Cobalamin disorder CblC presenting with hemolytic uremic syndrome and pulmonary hypertension. ( 28610805 )
2017
46
Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. ( 27799617 )
2017
47
Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. ( 28356668 )
2017
48
Case report: C3 glomerulopathy advancing atypical hemolytic uremic syndrome. ( 29150227 )
2017
49
Hemolytic Uremic Syndrome-associated Encephalopathy Successfully Treated with Corticosteroids. ( 28943538 )
2017
50
ASSESSMENT OF THE LEVEL OF KNOWLEDGE OF MEDICAL PERSONNEL IN DIARRHEA AND HEMOLYTIC-UREMIC SYNDROME. ( 29328045 )
2017

Variations for Hemolytic-Uremic Syndrome

Expression for Hemolytic-Uremic Syndrome

Search GEO for disease gene expression data for Hemolytic-Uremic Syndrome.

Pathways for Hemolytic-Uremic Syndrome

GO Terms for Hemolytic-Uremic Syndrome

Cellular components related to Hemolytic-Uremic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.91 C3 C5 CD46 CFB CFH CFHR1
2 extracellular space GO:0005615 9.81 ADAMTS13 C3 C5 CFB CFH CFHR1
3 extracellular region GO:0005576 9.36 ADAMTS13 C3 C5 CFB CFH CFHR1
4 blood microparticle GO:0072562 9.35 C3 CFB CFH CFHR1 CFHR3

Biological processes related to Hemolytic-Uremic Syndrome according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.81 C3 C5 CD46 CFB
2 innate immune response GO:0045087 9.8 C3 C5 CD46 CFB CFH CFI
3 blood coagulation GO:0007596 9.67 ADAMTS13 THBD VWF
4 complement activation, classical pathway GO:0006958 9.67 C3 C5 CD46 CFI
5 platelet activation GO:0030168 9.63 ADAMTS13 DGKE VWF
6 negative regulation of protein binding GO:0032091 9.61 CFHR1 CFHR2 CFHR5
7 hemostasis GO:0007599 9.58 ADAMTS13 THBD VWF
8 complement activation GO:0006956 9.55 C3 C5 CFB CFH CFHR1
9 positive regulation of vascular endothelial growth factor production GO:0010575 9.48 C3 C5
10 positive regulation of cytolysis GO:0045919 9.43 CFHR1 CFHR2 CFHR5
11 complement activation, alternative pathway GO:0006957 9.35 C3 C5 CFB CFH CFHR5
12 regulation of complement activation GO:0030449 9.32 C3 C5 CD46 CFB CFH CFHR1

Molecular functions related to Hemolytic-Uremic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endopeptidase inhibitor activity GO:0004866 8.62 C3 C5

Sources for Hemolytic-Uremic Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....